Therapeutic potential of the sphingosine kinase 2 inhibitor opaganib
Fuxun Huang, Peng Zhan, Xiujuan Shi, Yueyang Sun, Xingbo Song, Peilu Sun, Bo Liu · 2026
Read Therapeutic potential of the sphingosine kinase 2 inhibitor opaganib by Fuxun Huang, Peng Zhan, Xiujuan Shi, Yueyang Sun, Xingbo Song, Peilu Sun, Bo Liu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13234246.txt.
Description
Fuxun Huang and co-authors reviewed in 2026 the possible medical uses of opaganib, a drug taken by mouth. Opaganib blocks an enzyme called sphingosine kinase 2, which helps cells make a fat-like signal linked to growth and survival. The review explains how the drug also affects two related enzymes in human cells. Those actions can lower survival signals inside cells.
Evidence covered in the review points to activity against cancer, inflammation, and viral infection. Recent work discussed includes gut injury after radiation, harm from chemical exposure, and viruses such as COVID-19 and Ebola. Readers gain a map of how the drug works and which trials or studies should come next. The authors frame opaganib as a host-directed treatment worth further testing.
Catalog record
| CREATOR | Fuxun Huang, Peng Zhan, Xiujuan Shi, Yueyang Sun, Xingbo Song, Peilu Sun, Bo Liu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 94 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |